397 related articles for article (PubMed ID: 16758472)
1. A brief overview of mechanisms of mitochondrial toxicity from NRTIs.
Kohler JJ; Lewis W
Environ Mol Mutagen; 2007; 48(3-4):166-72. PubMed ID: 16758472
[TBL] [Abstract][Full Text] [Related]
2. Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy.
Lewis W
Antivir Ther; 2005; 10 Suppl 2():M13-27. PubMed ID: 16152703
[TBL] [Abstract][Full Text] [Related]
3. Possible ways nucleoside analogues can affect mitochondrial DNA content and gene expression during HIV therapy.
Côté HC
Antivir Ther; 2005; 10 Suppl 2():M3-11. PubMed ID: 16152702
[TBL] [Abstract][Full Text] [Related]
4. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.
Moyle G
Clin Ther; 2000 Aug; 22(8):911-36; discussion 898. PubMed ID: 10972629
[TBL] [Abstract][Full Text] [Related]
5. HIV and mitochondrial toxicity in children.
Foster C; Lyall H
J Antimicrob Chemother; 2008 Jan; 61(1):8-12. PubMed ID: 17999978
[TBL] [Abstract][Full Text] [Related]
6. Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA.
Koczor CA; Lewis W
Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1493-504. PubMed ID: 20929279
[TBL] [Abstract][Full Text] [Related]
7. An introduction to nucleoside and nucleotide analogues.
Squires KE
Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
[TBL] [Abstract][Full Text] [Related]
8. Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity.
Höschele D
Toxicol In Vitro; 2006 Aug; 20(5):535-46. PubMed ID: 16406476
[TBL] [Abstract][Full Text] [Related]
9. [Impact of reverse transcriptase inhibitors on sperm mitochondrial and genomic DNA in assisted reproduction techniques].
Sergerie M; Martinet S; Kiffer N; Teulé R; Pasquier C; Bujan L
Gynecol Obstet Fertil; 2004 Oct; 32(10):841-9. PubMed ID: 15501159
[TBL] [Abstract][Full Text] [Related]
10. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis identifies prohibitin down-regulation as a crucial event in the mitochondrial damage observed in HIV-infected patients.
Ciccosanti F; Corazzari M; Soldani F; Matarrese P; Pagliarini V; Iadevaia V; Tinari A; Zaccarelli M; Perfettini JL; Malorni W; Kroemer G; Antinori A; Fimia GM; Piacentini M
Antivir Ther; 2010; 15(3):377-90. PubMed ID: 20516557
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition.
Apostolova N; Blas-García A; Esplugues JV
Trends Pharmacol Sci; 2011 Dec; 32(12):715-25. PubMed ID: 21899897
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.
Kakuda TN
Clin Ther; 2000 Jun; 22(6):685-708. PubMed ID: 10929917
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial toxicity: myths and facts.
Moyle G
J HIV Ther; 2004 May; 9(2):45-7. PubMed ID: 15238876
[TBL] [Abstract][Full Text] [Related]
15. Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity.
Walker UA; Venhoff N
Antivir Ther; 2005; 10 Suppl 2():M117-23. PubMed ID: 16152713
[TBL] [Abstract][Full Text] [Related]
16. Update on mitochondrial toxicity: where are we now?
Walker UA
J HIV Ther; 2003 May; 8(2):32-5. PubMed ID: 12838162
[TBL] [Abstract][Full Text] [Related]
17. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy.
Haugaard SB; Andersen O; Pedersen SB; Dela F; Richelsen B; Nielsen JO; Madsbad S; Iversen J
J Med Virol; 2005 Sep; 77(1):29-38. PubMed ID: 16032748
[TBL] [Abstract][Full Text] [Related]
18. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective.
Lewis W; Day BJ; Copeland WC
Nat Rev Drug Discov; 2003 Oct; 2(10):812-22. PubMed ID: 14526384
[TBL] [Abstract][Full Text] [Related]
20. Hyperlactataemia in HIV-infected patients: the role of NRTI-treatment.
Vrouenraets SM; Treskes M; Regez RM; Troost N; Smulders YM; Weigel HM; Frissen PH; Brinkman K
Antivir Ther; 2002 Dec; 7(4):239-44. PubMed ID: 12553477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]